Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The CD20×CD3 bispecific added a later-line subcutaneous treatment option in follicular lymphoma. The FDA granted traditional approval for this use in November 2025.
What research teams should watch
Reconcile prior lines and program the follicular lymphoma-specific step-up schedule, with escalation plans for fever and neurologic symptoms.
PRIMARY RECORDS